BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Biden’s science team & early cancer detection: a BioCentury podcast

...eteplirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT). Fishburn says that Biden is also sending a “big message”...
BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

...good.“Representatives of the drug industry and trade organizations really want to try and push the message...
BioCentury | Jan 12, 2021
Management Tracks

HHS yanks rug from under FDA, reverses chief counsel nomination

...Counsel, will serve as the new Chief Counsel at the FDA.” The tweet included a message...
BioCentury | Dec 19, 2020
Product Development

Asymptomatic COVID-19 testing reaches inflection point

With the pandemic raging, regulators are breaking down the distinction between symptomatic and asymptomatic COVID-19 testing, and opening the door to individual self-screening. Communications from FDA...
BioCentury | Dec 10, 2020
Emerging Company Profile

Remix: targeting RNA modulating complexes

Start-up Remix aims to use its $81 million in seed and series A funding to correct disease-causing RNA dysregulation.  President and CSO Peter Smith founded Remix Therapeutics Inc. last year as an entrepreneur in residence...
BioCentury | Dec 4, 2020
Politics, Policy & Law

Trade groups move to derail rule that would tie drug prices with those in other countries

...think this rule sends such a negative message...
BioCentury | Dec 2, 2020
Product Development

Azar touts mAb COVID-19 therapies but NIH isn’t convinced

The Trump administration sent mixed messages about mAbs for COVID-19 Wednesday as HHS Secretary Alex Azar urged the media to encourage Americans to seek the therapies and an NIH panel said there aren’t...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...power and communications capabilities to convey the message...
BioCentury | Nov 19, 2020
Product Development

BMS Foundation, National Medical Fellowships commit $100M to boost trial diversity

...extend to the community, doesn’t extend to trusted voices within the community to deliver the message...
Items per page:
1 - 10 of 554
BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Biden’s science team & early cancer detection: a BioCentury podcast

...eteplirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT). Fishburn says that Biden is also sending a “big message”...
BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

...good.“Representatives of the drug industry and trade organizations really want to try and push the message...
BioCentury | Jan 12, 2021
Management Tracks

HHS yanks rug from under FDA, reverses chief counsel nomination

...Counsel, will serve as the new Chief Counsel at the FDA.” The tweet included a message...
BioCentury | Dec 19, 2020
Product Development

Asymptomatic COVID-19 testing reaches inflection point

With the pandemic raging, regulators are breaking down the distinction between symptomatic and asymptomatic COVID-19 testing, and opening the door to individual self-screening. Communications from FDA...
BioCentury | Dec 10, 2020
Emerging Company Profile

Remix: targeting RNA modulating complexes

Start-up Remix aims to use its $81 million in seed and series A funding to correct disease-causing RNA dysregulation.  President and CSO Peter Smith founded Remix Therapeutics Inc. last year as an entrepreneur in residence...
BioCentury | Dec 4, 2020
Politics, Policy & Law

Trade groups move to derail rule that would tie drug prices with those in other countries

...think this rule sends such a negative message...
BioCentury | Dec 2, 2020
Product Development

Azar touts mAb COVID-19 therapies but NIH isn’t convinced

The Trump administration sent mixed messages about mAbs for COVID-19 Wednesday as HHS Secretary Alex Azar urged the media to encourage Americans to seek the therapies and an NIH panel said there aren’t...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...power and communications capabilities to convey the message...
BioCentury | Nov 19, 2020
Product Development

BMS Foundation, National Medical Fellowships commit $100M to boost trial diversity

...extend to the community, doesn’t extend to trusted voices within the community to deliver the message...
Items per page:
1 - 10 of 554